profit from every $100 of sales.
$0$100
UroGen Pharma
$25.32-3.76% today
+9.5% in 1 year
1-year low $17.001-year high $50.29
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What UroGen Pharma sold, what it kept, and what it did with the cash.
Sales went from $64.4 million in 2022 to $110 million in 2025, with -$153 million of profit last year.
SalesProfit
UroGen Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| UroGen Pharma | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads UroGen Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 64 | 83 | 90 | 110 | |
| 57 | 73 | 82 | 97 | |
| -79 | -66 | -97 | -125 | |
| -98 | -82 | -110 | -136 | |
| -110 | -102 | -127 | -153 | |
| -4.79 | -3.55 | -2.96 | -3.19 | |
| 88.1% | 88.7% | 90.2% | 88.7% | |
| -122.8% | -79.2% | -107.1% | -113.7% | |
| -170.6% | -123.6% | -140.4% | -139.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 136 | 178 | 286 | 200 |
| Cash | 55 | 95 | 172 | 111 |
| Total debt | 99 | 99 | 123 | 128 |
| Total liabilities | 225 | 244 | 295 | 306 |
| -89 | -65 | -9 | -105 | |
| 23 | 29 | 43 | 48 | |
| -805.9% | -193.2% | -76.9% | -477.2% | |
| 122.9% | 156.8% | 1,441.3% | 145.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -88 | -76 | -97 | -162 | |
| 0 | 0 | 0 | 0 | |
| -88 | -77 | -97 | -163 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 11 | 9 | 13 | 12 |
Valuation
- –
- –
- –
- -12.9×
- 11.3×
- –
- –
- -13.1%
- -12.4%
- 0.0%
Profitability
- 88.7%
- -113.7%
- -139.8%
- -82.8%
- -50.9%
- -692.7%
- 121.5%
- -52.5%
- -53.3%
- 44.7%
Growth
- +19.5%
- –
- −67.7%
- –
- +21.1%
Financial health
- –
- -1.59
- 77.7%
- -2.8×
- 4.69
- 4.28
- 0.55
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 6%of 958
Bottom 3%of 884
Top 27%of 880
Bottom 7%of 988
What analysts expect
- Average price target
- $40.00
- Range
- $40.00 – $40.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.47 | -0.56 | +16.1% |
| Mar 2, 2026 | -0.54 | -0.52 | −4.2% |
| Nov 6, 2025 | -0.69 | -0.72 | +4.2% |
| Aug 7, 2025 | -1.05 | -0.82 | −28.0% |
| May 12, 2025 | -0.92 | -0.83 | −10.8% |
| Mar 10, 2025 | -0.80 | -0.69 | −15.9% |
| Nov 6, 2024 | -0.55 | -0.84 | +34.5% |
| Aug 13, 2024 | -0.91 | -0.82 | −11.0% |
News
UroGen expects profitability and positive cash flow in Q4 2026 as ZUSDURI grows 35% sequentiallySeeking Alpha · Nov 4, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
34No pass
Benjamin Graham
45No pass
Philip Fisher
50No pass
Peter Lynch
49No pass
Joel Greenblatt
2No pass
Charlie Munger
53No pass
Terry Smith
62Pass
Questions about UroGen Pharma
Is UroGen Pharma a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the UroGen Pharma AI analysis
What does UroGen Pharma do?
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It is in Biotechnology.
Does UroGen Pharma pay a dividend?
No. UroGen Pharma does not pay a dividend at the moment.
Is UroGen Pharma stock halal?
Yes. UroGen Pharma passes our halal screen: its business is permitted and its debt is 10% of its market value, under the 30% limit. How we check
How has UroGen Pharma stock done over the past year?
Up 9.5% over the past twelve months, to $25.32. It traded between $17.00 and $50.29 and is 49.7% below its high.
Who are UroGen Pharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with UroGen Pharma's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.